+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Degenerative Disc Disease Treatment Market By Drugs, By Route of Administration: Global Opportunity Analysis and Industry Forecast, 2023-2032

  • PDF Icon

    Report

  • 320 Pages
  • May 2024
  • Region: Global
  • Allied Market Research
  • ID: 5994145
UP TO OFF until Oct 24th 2024
The global degenerative disc disease treatment market is anticipated to reach $46.20 billion by 2032, growing from $28.03 billion in 2022 at a CAGR of 5.5% from 2023 to 2032.

Degenerative Disc Disease (DDD) refers to a condition characterized by the gradual deterioration of the intervertebral discs in the spine. These discs are soft, compressible structures that act as cushions between the vertebrae, providing flexibility and shock absorption to the spine. However, with age, or due to factors such as injury or wear and tear, these discs can degenerate, losing their ability to cushion the vertebrae effectively.

As the discs degenerate, they may lose height, become less flexible, and develop tears or cracks. This can lead to various symptoms, including localized or radiating pain, stiffness, weakness, and numbness or tingling sensations. DDD commonly affects the cervical (neck) and lumbar (lower back) regions of the spine, although it can occur anywhere along the spinal column.

The escalating prevalence of low back pain and neck pain among adults, coupled with the expanding geriatric population, is fueling the growth of the degenerative disc disease treatment market. Additionally, improved diagnostic techniques and greater awareness of spinal health have contributed to more people seeking treatment for DDD. This trend drives market growth as more individuals are diagnosed and require therapeutic interventions. Advances in medical technology, such as minimally invasive surgical techniques and regenerative medicine, have expanded the range of treatment options. Innovations like artificial discs and spinal cord stimulators are propelling the market forward. Consequently, this phenomenon propels the expansion of the degenerative disc disease treatment market throughout the forecast period.

Many of the advanced treatment options for DDD, such as spinal surgeries and regenerative therapies, can be expensive. This high cost can limit access to treatment for some patients and may also pose challenges for healthcare systems and insurance providers. While there are various treatment options available for DDD, none of them provide a definitive cure. Moreover, the efficacy of some treatments, such as spinal surgeries, can vary from patient to patient, leading to uncertainties about outcomes. All these factors are anticipated to restrain the market growth.

Continued advancements in medical technology, such as minimally invasive surgical techniques, robotic-assisted surgery, and imaging modalities like MRI and CT scans, offer opportunities to improve the diagnosis and treatment of DDD. These technologies can lead to more precise interventions, reduced recovery times, and better patient outcomes. The field of regenerative medicine holds promise for treating DDD by harnessing the body's natural healing processes. Stem cell therapy, platelet-rich plasma (PRP) injections, and tissue engineering approaches are being explored as potential treatments to repair or regenerate damaged intervertebral discs. Investing in research and development in this area could lead to groundbreaking therapies that address the underlying causes of DDD and provide long-lasting relief for patients. All these factors are anticipated to create opportunities in the coming years.

The key players profiled in this report include Medtronic plc, Johnson & Johnson Services, Inc., Zimmer Biomet Holdings, Inc., Stryker Corporation, Abbott Laboratories, Pfizer Inc., Novartis AG, AstraZeneca plc, Merck & Co., Inc., and Eli Lilly and Company. The market players are continuously striving to achieve an upper hand in this competitive market using strategies such as collaborations and acquisitions.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the degenerative disc disease treatment market analysis from 2022 to 2032 to identify the prevailing degenerative disc disease treatment market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the degenerative disc disease treatment market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global degenerative disc disease treatment market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • End user preferences and pain points
  • Investment Opportunities
  • Upcoming/New Entrant by Regions
  • Technology Trend Analysis
  • Distributor margin Analysis
  • New Product Development/ Product Matrix of Key Players
  • Patient/epidemiology data at country, region, global level
  • Regulatory Guidelines
  • Strategic Recommedations
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Criss-cross segment analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)
  • Market share analysis of players at global/region/country level
  • SWOT Analysis

Key Market Segments

By Drugs

  • Acetaminophen
  • NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)
  • Muscle Relaxants
  • Steroids

By Treatment Type

  • Occupational Therapy
  • Physical Therapy
  • Special Exercises
  • Medications
  • Weight Loss Surgery

By End Use

  • Hospitals
  • Clinics
  • Others

By Route of Administration

  • Oral
  • Injectable

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • UAE
  • South Africa
  • Rest of LAMEA

Key Market Players

  • Medtronic plc
  • Braun Melsungen AG
  • Pfizer Inc.
  • Novartis AG
  • Eli Lilly and Company
  • DiscGenics, Inc.
  • Spine BioPharma
  • FibroGenesis
  • Ferring B.V.
  • AstraZeneca Plc

 

Please note:

  • Online Access price format is valid for 60 days access. Printing is not enabled.
  • PDF Single and Enterprise price formats enable printing.

 

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.4. Market dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
3.5. Average Selling Price
3.6. Market Share Analysis
3.7. Brand Share Analysis
3.8. Trade Data Analysis
3.9. Product Consumption
3.10. Value Chain Analysis
3.11. Key Regulation Analysis
3.12. Patent Landscape
3.13. Regulatory Guidelines
3.14. Key Players Details
3.15. Reimbursement Scenario
CHAPTER 4: DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY DRUGS
4.1. Overview
4.1.1. Market size and forecast
4.2. Acetaminophen
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Muscle Relaxants
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
4.5. Steroids
4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market share analysis by country
CHAPTER 5: DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY TREATMENT TYPE
5.1. Overview
5.1.1. Market size and forecast
5.2. Occupational Therapy
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Physical Therapy
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Special Exercises
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
5.5. Medications
5.5.1. Key market trends, growth factors and opportunities
5.5.2. Market size and forecast, by region
5.5.3. Market share analysis by country
5.6. Weight Loss Surgery
5.6.1. Key market trends, growth factors and opportunities
5.6.2. Market size and forecast, by region
5.6.3. Market share analysis by country
CHAPTER 6: DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY END USE
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospitals
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Clinics
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Others
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
CHAPTER 7: DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
7.1. Overview
7.1.1. Market size and forecast
7.2. Oral
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by region
7.2.3. Market share analysis by country
7.3. Injectable
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast, by region
7.3.3. Market share analysis by country
CHAPTER 8: DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY REGION
8.1. Overview
8.1.1. Market size and forecast By Region
8.2. North America
8.2.1. Key market trends, growth factors and opportunities
8.2.2. Market size and forecast, by Drugs
8.2.3. Market size and forecast, by Treatment Type
8.2.4. Market size and forecast, by End Use
8.2.5. Market size and forecast, by Route of Administration
8.2.6. Market size and forecast, by country
8.2.6.1. U.S.
8.2.6.1.1. Market size and forecast, by Drugs
8.2.6.1.2. Market size and forecast, by Treatment Type
8.2.6.1.3. Market size and forecast, by End Use
8.2.6.1.4. Market size and forecast, by Route of Administration
8.2.6.2. Canada
8.2.6.2.1. Market size and forecast, by Drugs
8.2.6.2.2. Market size and forecast, by Treatment Type
8.2.6.2.3. Market size and forecast, by End Use
8.2.6.2.4. Market size and forecast, by Route of Administration
8.2.6.3. Mexico
8.2.6.3.1. Market size and forecast, by Drugs
8.2.6.3.2. Market size and forecast, by Treatment Type
8.2.6.3.3. Market size and forecast, by End Use
8.2.6.3.4. Market size and forecast, by Route of Administration
8.3. Europe
8.3.1. Key market trends, growth factors and opportunities
8.3.2. Market size and forecast, by Drugs
8.3.3. Market size and forecast, by Treatment Type
8.3.4. Market size and forecast, by End Use
8.3.5. Market size and forecast, by Route of Administration
8.3.6. Market size and forecast, by country
8.3.6.1. Germany
8.3.6.1.1. Market size and forecast, by Drugs
8.3.6.1.2. Market size and forecast, by Treatment Type
8.3.6.1.3. Market size and forecast, by End Use
8.3.6.1.4. Market size and forecast, by Route of Administration
8.3.6.2. UK
8.3.6.2.1. Market size and forecast, by Drugs
8.3.6.2.2. Market size and forecast, by Treatment Type
8.3.6.2.3. Market size and forecast, by End Use
8.3.6.2.4. Market size and forecast, by Route of Administration
8.3.6.3. France
8.3.6.3.1. Market size and forecast, by Drugs
8.3.6.3.2. Market size and forecast, by Treatment Type
8.3.6.3.3. Market size and forecast, by End Use
8.3.6.3.4. Market size and forecast, by Route of Administration
8.3.6.4. Spain
8.3.6.4.1. Market size and forecast, by Drugs
8.3.6.4.2. Market size and forecast, by Treatment Type
8.3.6.4.3. Market size and forecast, by End Use
8.3.6.4.4. Market size and forecast, by Route of Administration
8.3.6.5. Italy
8.3.6.5.1. Market size and forecast, by Drugs
8.3.6.5.2. Market size and forecast, by Treatment Type
8.3.6.5.3. Market size and forecast, by End Use
8.3.6.5.4. Market size and forecast, by Route of Administration
8.3.6.6. Rest of Europe
8.3.6.6.1. Market size and forecast, by Drugs
8.3.6.6.2. Market size and forecast, by Treatment Type
8.3.6.6.3. Market size and forecast, by End Use
8.3.6.6.4. Market size and forecast, by Route of Administration
8.4. Asia-Pacific
8.4.1. Key market trends, growth factors and opportunities
8.4.2. Market size and forecast, by Drugs
8.4.3. Market size and forecast, by Treatment Type
8.4.4. Market size and forecast, by End Use
8.4.5. Market size and forecast, by Route of Administration
8.4.6. Market size and forecast, by country
8.4.6.1. China
8.4.6.1.1. Market size and forecast, by Drugs
8.4.6.1.2. Market size and forecast, by Treatment Type
8.4.6.1.3. Market size and forecast, by End Use
8.4.6.1.4. Market size and forecast, by Route of Administration
8.4.6.2. Japan
8.4.6.2.1. Market size and forecast, by Drugs
8.4.6.2.2. Market size and forecast, by Treatment Type
8.4.6.2.3. Market size and forecast, by End Use
8.4.6.2.4. Market size and forecast, by Route of Administration
8.4.6.3. India
8.4.6.3.1. Market size and forecast, by Drugs
8.4.6.3.2. Market size and forecast, by Treatment Type
8.4.6.3.3. Market size and forecast, by End Use
8.4.6.3.4. Market size and forecast, by Route of Administration
8.4.6.4. South Korea
8.4.6.4.1. Market size and forecast, by Drugs
8.4.6.4.2. Market size and forecast, by Treatment Type
8.4.6.4.3. Market size and forecast, by End Use
8.4.6.4.4. Market size and forecast, by Route of Administration
8.4.6.5. Australia
8.4.6.5.1. Market size and forecast, by Drugs
8.4.6.5.2. Market size and forecast, by Treatment Type
8.4.6.5.3. Market size and forecast, by End Use
8.4.6.5.4. Market size and forecast, by Route of Administration
8.4.6.6. Rest of Asia-Pacific
8.4.6.6.1. Market size and forecast, by Drugs
8.4.6.6.2. Market size and forecast, by Treatment Type
8.4.6.6.3. Market size and forecast, by End Use
8.4.6.6.4. Market size and forecast, by Route of Administration
8.5. LAMEA
8.5.1. Key market trends, growth factors and opportunities
8.5.2. Market size and forecast, by Drugs
8.5.3. Market size and forecast, by Treatment Type
8.5.4. Market size and forecast, by End Use
8.5.5. Market size and forecast, by Route of Administration
8.5.6. Market size and forecast, by country
8.5.6.1. Brazil
8.5.6.1.1. Market size and forecast, by Drugs
8.5.6.1.2. Market size and forecast, by Treatment Type
8.5.6.1.3. Market size and forecast, by End Use
8.5.6.1.4. Market size and forecast, by Route of Administration
8.5.6.2. Saudi Arabia
8.5.6.2.1. Market size and forecast, by Drugs
8.5.6.2.2. Market size and forecast, by Treatment Type
8.5.6.2.3. Market size and forecast, by End Use
8.5.6.2.4. Market size and forecast, by Route of Administration
8.5.6.3. UAE
8.5.6.3.1. Market size and forecast, by Drugs
8.5.6.3.2. Market size and forecast, by Treatment Type
8.5.6.3.3. Market size and forecast, by End Use
8.5.6.3.4. Market size and forecast, by Route of Administration
8.5.6.4. South Africa
8.5.6.4.1. Market size and forecast, by Drugs
8.5.6.4.2. Market size and forecast, by Treatment Type
8.5.6.4.3. Market size and forecast, by End Use
8.5.6.4.4. Market size and forecast, by Route of Administration
8.5.6.5. Rest of LAMEA
8.5.6.5.1. Market size and forecast, by Drugs
8.5.6.5.2. Market size and forecast, by Treatment Type
8.5.6.5.3. Market size and forecast, by End Use
8.5.6.5.4. Market size and forecast, by Route of Administration
CHAPTER 9: COMPETITIVE LANDSCAPE
9.1. Introduction
9.2. Top winning strategies
9.3. Product mapping of top 10 player
9.4. Competitive dashboard
9.5. Competitive heatmap
9.6. Top player positioning, 2022
CHAPTER 10: COMPANY PROFILES
10.1. Medtronic plc
10.1.1. Company overview
10.1.2. Key executives
10.1.3. Company snapshot
10.1.4. Operating business segments
10.1.5. Product portfolio
10.1.6. Business performance
10.1.7. Key strategic moves and developments
10.2. Braun Melsungen AG
10.2.1. Company overview
10.2.2. Key executives
10.2.3. Company snapshot
10.2.4. Operating business segments
10.2.5. Product portfolio
10.2.6. Business performance
10.2.7. Key strategic moves and developments
10.3. Pfizer Inc.
10.3.1. Company overview
10.3.2. Key executives
10.3.3. Company snapshot
10.3.4. Operating business segments
10.3.5. Product portfolio
10.3.6. Business performance
10.3.7. Key strategic moves and developments
10.4. Novartis AG
10.4.1. Company overview
10.4.2. Key executives
10.4.3. Company snapshot
10.4.4. Operating business segments
10.4.5. Product portfolio
10.4.6. Business performance
10.4.7. Key strategic moves and developments
10.5. Eli Lilly and Company
10.5.1. Company overview
10.5.2. Key executives
10.5.3. Company snapshot
10.5.4. Operating business segments
10.5.5. Product portfolio
10.5.6. Business performance
10.5.7. Key strategic moves and developments
10.6. DiscGenics, Inc.
10.6.1. Company overview
10.6.2. Key executives
10.6.3. Company snapshot
10.6.4. Operating business segments
10.6.5. Product portfolio
10.6.6. Business performance
10.6.7. Key strategic moves and developments
10.7. Spine BioPharma
10.7.1. Company overview
10.7.2. Key executives
10.7.3. Company snapshot
10.7.4. Operating business segments
10.7.5. Product portfolio
10.7.6. Business performance
10.7.7. Key strategic moves and developments
10.8. FibroGenesis
10.8.1. Company overview
10.8.2. Key executives
10.8.3. Company snapshot
10.8.4. Operating business segments
10.8.5. Product portfolio
10.8.6. Business performance
10.8.7. Key strategic moves and developments
10.9. Ferring B.V.
10.9.1. Company overview
10.9.2. Key executives
10.9.3. Company snapshot
10.9.4. Operating business segments
10.9.5. Product portfolio
10.9.6. Business performance
10.9.7. Key strategic moves and developments
10.10. AstraZeneca Plc
10.10.1. Company overview
10.10.2. Key executives
10.10.3. Company snapshot
10.10.4. Operating business segments
10.10.5. Product portfolio
10.10.6. Business performance
10.10.7. Key strategic moves and developments
LIST OF TABLES
TABLE 01. GLOBAL DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
TABLE 02. DEGENERATIVE DISC DISEASE TREATMENT MARKET FOR ACETAMINOPHEN, BY REGION, 2022-2032 ($MILLION)
TABLE 03. DEGENERATIVE DISC DISEASE TREATMENT MARKET FOR NSAIDS (NON-STEROIDAL ANTI-INFLAMMATORY DRUGS), BY REGION, 2022-2032 ($MILLION)
TABLE 04. DEGENERATIVE DISC DISEASE TREATMENT MARKET FOR MUSCLE RELAXANTS, BY REGION, 2022-2032 ($MILLION)
TABLE 05. DEGENERATIVE DISC DISEASE TREATMENT MARKET FOR STEROIDS, BY REGION, 2022-2032 ($MILLION)
TABLE 06. GLOBAL DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 07. DEGENERATIVE DISC DISEASE TREATMENT MARKET FOR OCCUPATIONAL THERAPY, BY REGION, 2022-2032 ($MILLION)
TABLE 08. DEGENERATIVE DISC DISEASE TREATMENT MARKET FOR PHYSICAL THERAPY, BY REGION, 2022-2032 ($MILLION)
TABLE 09. DEGENERATIVE DISC DISEASE TREATMENT MARKET FOR SPECIAL EXERCISES, BY REGION, 2022-2032 ($MILLION)
TABLE 10. DEGENERATIVE DISC DISEASE TREATMENT MARKET FOR MEDICATIONS, BY REGION, 2022-2032 ($MILLION)
TABLE 11. DEGENERATIVE DISC DISEASE TREATMENT MARKET FOR WEIGHT LOSS SURGERY, BY REGION, 2022-2032 ($MILLION)
TABLE 12. GLOBAL DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY END USE, 2022-2032 ($MILLION)
TABLE 13. DEGENERATIVE DISC DISEASE TREATMENT MARKET FOR HOSPITALS, BY REGION, 2022-2032 ($MILLION)
TABLE 14. DEGENERATIVE DISC DISEASE TREATMENT MARKET FOR CLINICS, BY REGION, 2022-2032 ($MILLION)
TABLE 15. DEGENERATIVE DISC DISEASE TREATMENT MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 16. GLOBAL DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 17. DEGENERATIVE DISC DISEASE TREATMENT MARKET FOR ORAL, BY REGION, 2022-2032 ($MILLION)
TABLE 18. DEGENERATIVE DISC DISEASE TREATMENT MARKET FOR INJECTABLE, BY REGION, 2022-2032 ($MILLION)
TABLE 19. DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 20. NORTH AMERICA DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
TABLE 21. NORTH AMERICA DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 22. NORTH AMERICA DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY END USE, 2022-2032 ($MILLION)
TABLE 23. NORTH AMERICA DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 24. NORTH AMERICA DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 25. U.S. DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
TABLE 26. U.S. DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 27. U.S. DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY END USE, 2022-2032 ($MILLION)
TABLE 28. U.S. DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 29. CANADA DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
TABLE 30. CANADA DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 31. CANADA DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY END USE, 2022-2032 ($MILLION)
TABLE 32. CANADA DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 33. MEXICO DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
TABLE 34. MEXICO DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 35. MEXICO DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY END USE, 2022-2032 ($MILLION)
TABLE 36. MEXICO DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 37. EUROPE DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
TABLE 38. EUROPE DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 39. EUROPE DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY END USE, 2022-2032 ($MILLION)
TABLE 40. EUROPE DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 41. EUROPE DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 42. GERMANY DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
TABLE 43. GERMANY DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 44. GERMANY DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY END USE, 2022-2032 ($MILLION)
TABLE 45. GERMANY DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 46. UK DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
TABLE 47. UK DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 48. UK DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY END USE, 2022-2032 ($MILLION)
TABLE 49. UK DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 50. FRANCE DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
TABLE 51. FRANCE DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 52. FRANCE DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY END USE, 2022-2032 ($MILLION)
TABLE 53. FRANCE DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 54. SPAIN DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
TABLE 55. SPAIN DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 56. SPAIN DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY END USE, 2022-2032 ($MILLION)
TABLE 57. SPAIN DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 58. ITALY DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
TABLE 59. ITALY DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 60. ITALY DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY END USE, 2022-2032 ($MILLION)
TABLE 61. ITALY DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 62. REST OF EUROPE DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
TABLE 63. REST OF EUROPE DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 64. REST OF EUROPE DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY END USE, 2022-2032 ($MILLION)
TABLE 65. REST OF EUROPE DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 66. ASIA-PACIFIC DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
TABLE 67. ASIA-PACIFIC DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 68. ASIA-PACIFIC DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY END USE, 2022-2032 ($MILLION)
TABLE 69. ASIA-PACIFIC DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 70. ASIA-PACIFIC DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 71. CHINA DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
TABLE 72. CHINA DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 73. CHINA DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY END USE, 2022-2032 ($MILLION)
TABLE 74. CHINA DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 75. JAPAN DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
TABLE 76. JAPAN DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 77. JAPAN DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY END USE, 2022-2032 ($MILLION)
TABLE 78. JAPAN DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 79. INDIA DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
TABLE 80. INDIA DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 81. INDIA DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY END USE, 2022-2032 ($MILLION)
TABLE 82. INDIA DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 83. SOUTH KOREA DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
TABLE 84. SOUTH KOREA DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 85. SOUTH KOREA DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY END USE, 2022-2032 ($MILLION)
TABLE 86. SOUTH KOREA DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 87. AUSTRALIA DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
TABLE 88. AUSTRALIA DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 89. AUSTRALIA DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY END USE, 2022-2032 ($MILLION)
TABLE 90. AUSTRALIA DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 91. REST OF ASIA-PACIFIC DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
TABLE 92. REST OF ASIA-PACIFIC DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 93. REST OF ASIA-PACIFIC DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY END USE, 2022-2032 ($MILLION)
TABLE 94. REST OF ASIA-PACIFIC DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 95. LAMEA DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
TABLE 96. LAMEA DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 97. LAMEA DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY END USE, 2022-2032 ($MILLION)
TABLE 98. LAMEA DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 99. LAMEA DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 100. BRAZIL DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
TABLE 101. BRAZIL DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 102. BRAZIL DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY END USE, 2022-2032 ($MILLION)
TABLE 103. BRAZIL DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 104. SAUDI ARABIA DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
TABLE 105. SAUDI ARABIA DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 106. SAUDI ARABIA DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY END USE, 2022-2032 ($MILLION)
TABLE 107. SAUDI ARABIA DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 108. UAE DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
TABLE 109. UAE DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 110. UAE DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY END USE, 2022-2032 ($MILLION)
TABLE 111. UAE DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 112. SOUTH AFRICA DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
TABLE 113. SOUTH AFRICA DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 114. SOUTH AFRICA DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY END USE, 2022-2032 ($MILLION)
TABLE 115. SOUTH AFRICA DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 116. REST OF LAMEA DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
TABLE 117. REST OF LAMEA DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 118. REST OF LAMEA DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY END USE, 2022-2032 ($MILLION)
TABLE 119. REST OF LAMEA DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 120. MEDTRONIC PLC: KEY EXECUTIVES
TABLE 121. MEDTRONIC PLC: COMPANY SNAPSHOT
TABLE 122. MEDTRONIC PLC: PRODUCT SEGMENTS
TABLE 123. MEDTRONIC PLC: SERVICE SEGMENTS
TABLE 124. MEDTRONIC PLC: PRODUCT PORTFOLIO
TABLE 125. MEDTRONIC PLC: KEY STRATERGIES
TABLE 126. BRAUN MELSUNGEN AG: KEY EXECUTIVES
TABLE 127. BRAUN MELSUNGEN AG: COMPANY SNAPSHOT
TABLE 128. BRAUN MELSUNGEN AG: PRODUCT SEGMENTS
TABLE 129. BRAUN MELSUNGEN AG: SERVICE SEGMENTS
TABLE 130. BRAUN MELSUNGEN AG: PRODUCT PORTFOLIO
TABLE 131. BRAUN MELSUNGEN AG: KEY STRATERGIES
TABLE 132. PFIZER INC.: KEY EXECUTIVES
TABLE 133. PFIZER INC.: COMPANY SNAPSHOT
TABLE 134. PFIZER INC.: PRODUCT SEGMENTS
TABLE 135. PFIZER INC.: SERVICE SEGMENTS
TABLE 136. PFIZER INC.: PRODUCT PORTFOLIO
TABLE 137. PFIZER INC.: KEY STRATERGIES
TABLE 138. NOVARTIS AG: KEY EXECUTIVES
TABLE 139. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 140. NOVARTIS AG: PRODUCT SEGMENTS
TABLE 141. NOVARTIS AG: SERVICE SEGMENTS
TABLE 142. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 143. NOVARTIS AG: KEY STRATERGIES
TABLE 144. ELI LILLY AND COMPANY: KEY EXECUTIVES
TABLE 145. ELI LILLY AND COMPANY: COMPANY SNAPSHOT
TABLE 146. ELI LILLY AND COMPANY: PRODUCT SEGMENTS
TABLE 147. ELI LILLY AND COMPANY: SERVICE SEGMENTS
TABLE 148. ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
TABLE 149. ELI LILLY AND COMPANY: KEY STRATERGIES
TABLE 150. DISCGENICS, INC.: KEY EXECUTIVES
TABLE 151. DISCGENICS, INC.: COMPANY SNAPSHOT
TABLE 152. DISCGENICS, INC.: PRODUCT SEGMENTS
TABLE 153. DISCGENICS, INC.: SERVICE SEGMENTS
TABLE 154. DISCGENICS, INC.: PRODUCT PORTFOLIO
TABLE 155. DISCGENICS, INC.: KEY STRATERGIES
TABLE 156. SPINE BIOPHARMA: KEY EXECUTIVES
TABLE 157. SPINE BIOPHARMA: COMPANY SNAPSHOT
TABLE 158. SPINE BIOPHARMA: PRODUCT SEGMENTS
TABLE 159. SPINE BIOPHARMA: SERVICE SEGMENTS
TABLE 160. SPINE BIOPHARMA: PRODUCT PORTFOLIO
TABLE 161. SPINE BIOPHARMA: KEY STRATERGIES
TABLE 162. FIBROGENESIS: KEY EXECUTIVES
TABLE 163. FIBROGENESIS: COMPANY SNAPSHOT
TABLE 164. FIBROGENESIS: PRODUCT SEGMENTS
TABLE 165. FIBROGENESIS: SERVICE SEGMENTS
TABLE 166. FIBROGENESIS: PRODUCT PORTFOLIO
TABLE 167. FIBROGENESIS: KEY STRATERGIES
TABLE 168. FERRING B.V.: KEY EXECUTIVES
TABLE 169. FERRING B.V.: COMPANY SNAPSHOT
TABLE 170. FERRING B.V.: PRODUCT SEGMENTS
TABLE 171. FERRING B.V.: SERVICE SEGMENTS
TABLE 172. FERRING B.V.: PRODUCT PORTFOLIO
TABLE 173. FERRING B.V.: KEY STRATERGIES
TABLE 174. ASTRAZENECA PLC: KEY EXECUTIVES
TABLE 175. ASTRAZENECA PLC: COMPANY SNAPSHOT
TABLE 176. ASTRAZENECA PLC: PRODUCT SEGMENTS
TABLE 177. ASTRAZENECA PLC: SERVICE SEGMENTS
TABLE 178. ASTRAZENECA PLC: PRODUCT PORTFOLIO
TABLE 179. ASTRAZENECA PLC: KEY STRATERGIES
LIST OF FIGURES
FIGURE 01. DEGENERATIVE DISC DISEASE TREATMENT MARKET, 2022-2032
FIGURE 02. SEGMENTATION OF DEGENERATIVE DISC DISEASE TREATMENT MARKET,2022-2032
FIGURE 03. TOP IMPACTING FACTORS IN DEGENERATIVE DISC DISEASE TREATMENT MARKET
FIGURE 04. TOP INVESTMENT POCKETS IN DEGENERATIVE DISC DISEASE TREATMENT MARKET (2023-2032)
FIGURE 05. BARGAINING POWER OF SUPPLIERS
FIGURE 06. BARGAINING POWER OF BUYERS
FIGURE 07. THREAT OF SUBSTITUTION
FIGURE 08. THREAT OF SUBSTITUTION
FIGURE 09. COMPETITIVE RIVALRY
FIGURE 10. GLOBAL DEGENERATIVE DISC DISEASE TREATMENT MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 11. IMPACT OF KEY REGULATION: DEGENERATIVE DISC DISEASE TREATMENT MARKET
FIGURE 12. PATENT ANALYSIS BY COMPANY
FIGURE 13. PATENT ANALYSIS BY COUNTRY
FIGURE 14. DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY DRUGS, 2022 AND 2032(%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF DEGENERATIVE DISC DISEASE TREATMENT MARKET FOR ACETAMINOPHEN, BY COUNTRY 2022 AND 2032(%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF DEGENERATIVE DISC DISEASE TREATMENT MARKET FOR NSAIDS (NON-STEROIDAL ANTI-INFLAMMATORY DRUGS), BY COUNTRY 2022 AND 2032(%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF DEGENERATIVE DISC DISEASE TREATMENT MARKET FOR MUSCLE RELAXANTS, BY COUNTRY 2022 AND 2032(%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF DEGENERATIVE DISC DISEASE TREATMENT MARKET FOR STEROIDS, BY COUNTRY 2022 AND 2032(%)
FIGURE 19. DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2022 AND 2032(%)
FIGURE 20. COMPARATIVE SHARE ANALYSIS OF DEGENERATIVE DISC DISEASE TREATMENT MARKET FOR OCCUPATIONAL THERAPY, BY COUNTRY 2022 AND 2032(%)
FIGURE 21. COMPARATIVE SHARE ANALYSIS OF DEGENERATIVE DISC DISEASE TREATMENT MARKET FOR PHYSICAL THERAPY, BY COUNTRY 2022 AND 2032(%)
FIGURE 22. COMPARATIVE SHARE ANALYSIS OF DEGENERATIVE DISC DISEASE TREATMENT MARKET FOR SPECIAL EXERCISES, BY COUNTRY 2022 AND 2032(%)
FIGURE 23. COMPARATIVE SHARE ANALYSIS OF DEGENERATIVE DISC DISEASE TREATMENT MARKET FOR MEDICATIONS, BY COUNTRY 2022 AND 2032(%)
FIGURE 24. COMPARATIVE SHARE ANALYSIS OF DEGENERATIVE DISC DISEASE TREATMENT MARKET FOR WEIGHT LOSS SURGERY, BY COUNTRY 2022 AND 2032(%)
FIGURE 25. DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY END USE, 2022 AND 2032(%)
FIGURE 26. COMPARATIVE SHARE ANALYSIS OF DEGENERATIVE DISC DISEASE TREATMENT MARKET FOR HOSPITALS, BY COUNTRY 2022 AND 2032(%)
FIGURE 27. COMPARATIVE SHARE ANALYSIS OF DEGENERATIVE DISC DISEASE TREATMENT MARKET FOR CLINICS, BY COUNTRY 2022 AND 2032(%)
FIGURE 28. COMPARATIVE SHARE ANALYSIS OF DEGENERATIVE DISC DISEASE TREATMENT MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 29. DEGENERATIVE DISC DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022 AND 2032(%)
FIGURE 30. COMPARATIVE SHARE ANALYSIS OF DEGENERATIVE DISC DISEASE TREATMENT MARKET FOR ORAL, BY COUNTRY 2022 AND 2032(%)
FIGURE 31. COMPARATIVE SHARE ANALYSIS OF DEGENERATIVE DISC DISEASE TREATMENT MARKET FOR INJECTABLE, BY COUNTRY 2022 AND 2032(%)
FIGURE 32. DEGENERATIVE DISC DISEASE TREATMENT MARKET BY REGION, 2022 AND 2032(%)
FIGURE 33. U.S. DEGENERATIVE DISC DISEASE TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 34. CANADA DEGENERATIVE DISC DISEASE TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 35. MEXICO DEGENERATIVE DISC DISEASE TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 36. GERMANY DEGENERATIVE DISC DISEASE TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 37. UK DEGENERATIVE DISC DISEASE TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 38. FRANCE DEGENERATIVE DISC DISEASE TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 39. SPAIN DEGENERATIVE DISC DISEASE TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 40. ITALY DEGENERATIVE DISC DISEASE TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 41. REST OF EUROPE DEGENERATIVE DISC DISEASE TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 42. CHINA DEGENERATIVE DISC DISEASE TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 43. JAPAN DEGENERATIVE DISC DISEASE TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 44. INDIA DEGENERATIVE DISC DISEASE TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 45. SOUTH KOREA DEGENERATIVE DISC DISEASE TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 46. AUSTRALIA DEGENERATIVE DISC DISEASE TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 47. REST OF ASIA-PACIFIC DEGENERATIVE DISC DISEASE TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 48. BRAZIL DEGENERATIVE DISC DISEASE TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 49. SAUDI ARABIA DEGENERATIVE DISC DISEASE TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 50. UAE DEGENERATIVE DISC DISEASE TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 51. SOUTH AFRICA DEGENERATIVE DISC DISEASE TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 52. REST OF LAMEA DEGENERATIVE DISC DISEASE TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 53. TOP WINNING STRATEGIES, BY YEAR
FIGURE 54. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 55. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 56. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 57. COMPETITIVE DASHBOARD
FIGURE 58. COMPETITIVE HEATMAP: DEGENERATIVE DISC DISEASE TREATMENT MARKET
FIGURE 59. TOP PLAYER POSITIONING, 2022

Companies Mentioned

  • Medtronic plc
  • Braun Melsungen AG
  • Pfizer Inc.
  • Novartis AG
  • Eli Lilly and Company
  • DiscGenics, Inc.
  • Spine BioPharma
  • FibroGenesis
  • Ferring B.V.
  • AstraZeneca Plc

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...